Biora Therapeutics (BIOR) Accelerates Debt Reduction and Raises Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
December 18, 2023 8:00 AM ESTTransaction results in nearly 60% reduction in net debt and brings $16.7 million in new capital for the company
Demonstrates investor confidence in near-term catalysts for NaviCap and BioJet platforms
SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investors Athyrium Capital Management, Davidson Kempner Capital Management, and Highbridge Capital Management to reduce the companys net debt by 60% through a convertible note exchange which also brings $16.7 million in new... More
